步長製藥(603858.SH):控股子公司擬設立子公司蘇州合璞醫療器械
格隆匯3月18日丨步長製藥(603858.SH)公佈,根據公司總體發展規劃,爲促進公司控股子公司上海合璞醫療科技有限公司(簡稱“上海合璞醫療科技”)的經營發展,上海合璞醫療科技擬與蘇州工業園區明普醫療科技有限公司(簡稱“明普醫療”)共同投資設立新公司蘇州合璞醫療器械有限公司(暫定名,最終名稱以工商部門覈準登記爲準)(簡稱“蘇州合璞醫療器械”)。蘇州合璞醫療器械註冊資本200萬元,上海合璞醫療科技出資140萬元,持股比例70%,明普醫療出資60萬元,持股比例30%。本次投資完成後,蘇州合璞醫療器械將會納入公司合併報表範圍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.